The World Health Organisation (WHO) has recommended a Phase III trial of an Ebola vaccine to test whether it can protect against Bundibugyo virus disease.
WHO Director-General, Tedros Ghebreyesus, disclosed this in a video posted on his official X account on Thursday.
Ghebreyesus said two vaccines specifically developed against the Bundibugyo virus had entered Phase I safety trials in humans. At the same time, new animal studies had shown promising evidence that Ervebo, an Ebola vaccine, could also provide cross-protection against the virus.
He said the findings prompted WHO to recommend Ervebo for inclusion in a Phase III trial, which the organisation hopes to begin as soon as possible.
However, it is not yet known whether Ervebo can protect humans against Bundibugyo virus disease.
